Home › Companies › Syndax Pharmaceuticals, Inc. › 2024-2025
Compiled from SEC Form N-PX filings and Syndax Pharmaceuticals, Inc.’s Form 8-K, filed 2025-05-16 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Syndax Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Syndax Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-05-16 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Keith A. Katkin | 53,552,483 | -- | -- | 12,880,619 | 4,852,212 | Majority: yes |
| Elect Director: Dennis G. Podlesak | 47,082,144 | -- | -- | 19,350,958 | 4,852,212 | Majority: yes |
| Elect Director: Aleksandra Rizo, M.D., Ph.D. | 63,139,437 | -- | -- | 3,293,665 | 4,852,212 | Majority: yes |
| Proposal 2: Advisory vote on executive compensation: | 62,495,031 | 3,829,672 | 108,399 | -- | 4,852,212 | Majority: yes |
| Proposal 3: Ratification of selection of independent registered public accounting firm: | 71,183,107 | 71,909 | 30,298 | -- | -- | Majority: yes |
Source: Syndax Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2025-05-16 — read the filing on EDGAR.
Each item below shows how the 219 asset managers that disclosed a Syndax Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Syndax Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 11 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Syndax Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: Advisory vote on executive compensation:”): 62,495,031 for, 3,829,672 against, per its Form 8-K filed 2025-05-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 86,047,032 outstanding shares: 73% for, 4% against (77% of the company cast a for/against vote).
The 217 asset managers below cast 97% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Kynam Capital Management, LP | 7,541,277 | 0 | 0 | 0 | For |
| BlackRock | 7,320,239 | 0 | 0 | 0 | For |
| State Street | 5,441,468 | 26,808 | 0 | 0 | For |
| Vanguard | 4,927,759 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 4,212,270 | 0 | 0 | 0 | For |
| Fidelity | 2,116,084 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,024,784 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 2,010,667 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 1,993,799 | 0 | 0 | 0 | For |
| Woodline Partners LP | 1,890,540 | 0 | 0 | 0 | For |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 1,804,360 | 0 | 0 | 0 | For |
| Catalio Capital Management, LP | 1,537,587 | 0 | 0 | 0 | For |
| Charles Schwab | 1,386,793 | 0 | 0 | 0 | For |
| Point72 | 1,249,353 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 1,221,269 | 0 | 0 | Against |
| MUTUAL FUND SERIES TRUST | 1,178,062 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,165,927 | 0 | 0 | 0 | For |
| Aisling Capital Management LP | 1,025,000 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 955,237 | 0 | 0 | 0 | For |
| PFM Health Sciences, LP | 926,424 | 0 | 0 | 0 | For |
| Avidity Partners Management LP | 925,000 | 0 | 0 | 0 | For |
| SILVERARC CAPITAL MANAGEMENT, LLC | 755,304 | 0 | 0 | 0 | For |
| Octagon Capital Advisors LP | 751,819 | 0 | 0 | 0 | For |
| Two Sigma | 749,754 | 0 | 0 | 0 | For |
| Northern Trust | 694,909 | 4,549 | 0 | 0 | For |
Showing the 25 largest of 217 asset managers. See all 217 in the interactive database.
Combines 3 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Syndax Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Aleksandra Rizo, M.D., Ph.D.”): 63,139,437 for, 3,293,665 withheld, per its Form 8-K filed 2025-05-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 86,047,032 outstanding shares: 73% for, 4% withheld (77% of the company cast a for/withheld vote).
The 55 asset managers below cast 100% of the shares they voted on this item FOR (18,049,373 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,649,438 | 0 | 0 | 0 | For |
| BlackRock | 3,921,294 | 0 | 0 | 0 | For |
| Fidelity | 1,965,078 | 0 | 0 | 0 | For |
| State Street | 1,901,899 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,178,062 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,165,927 | 0 | 0 | 0 | For |
| Charles Schwab | 693,127 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 305,130 | 0 | Abstain |
| Exchange Place Advisors Trust | 280,520 | 0 | 0 | 0 | For |
| Goldman Sachs | 227,788 | 0 | 0 | 0 | For |
| Equitable | 129,993 | 0 | 83,950 | 0 | For |
| TIAA | 200,197 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 180,000 | 0 | 0 | 0 | For |
| JPMorgan | 150,989 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 141,074 | 0 | 0 | 0 | For |
| Thornburg | 133,548 | 0 | 0 | 0 | For |
| Jackson National | 96,967 | 0 | 8,137 | 0 | For |
| Victory Capital | 103,834 | 0 | 0 | 0 | For |
| Aberdeen | 99,340 | 0 | 0 | 0 | For |
| Brighthouse | 67,260 | 0 | 22,313 | 0 | For |
| Lincoln Financial | 77,862 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 71,404 | 0 | 0 | 0 | For |
| John Hancock | 60,983 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 55,820 | 0 | 0 | 0 | For |
| ProShares | 52,590 | 0 | 0 | 0 | For |
Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.
Combines 2 wordings of this item as funds reported it.
71% Majority: yes · of votes cast
Syndax Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Dennis G. Podlesak”): 47,082,144 for, 19,350,958 withheld, per its Form 8-K filed 2025-05-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 86,047,032 outstanding shares: 54.7% for, 22% withheld (77% of the company cast a for/withheld vote).
The 55 asset managers below cast 100% of the shares they voted on this item FOR (14,949,308 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,649,438 | 0 | 0 | 0 | For |
| BlackRock | 3,921,294 | 0 | 0 | 0 | For |
| Fidelity | 1,965,078 | 0 | 0 | 0 | For |
| State Street | 3,288 | 0 | 1,898,611 | 0 | Abstain |
| MUTUAL FUND SERIES TRUST | 1,178,062 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,165,927 | 0 | 0 | 0 | For |
| Charles Schwab | 693,127 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 305,130 | 0 | Abstain |
| Exchange Place Advisors Trust | 280,520 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 227,788 | 0 | Abstain |
| Equitable | 129,993 | 0 | 83,950 | 0 | For |
| TIAA | 200,197 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 180,000 | 0 | Abstain |
| JPMorgan | 150,989 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 141,074 | 0 | 0 | 0 | For |
| Thornburg | 133,548 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 105,104 | 0 | Abstain |
| Victory Capital | 0 | 0 | 103,834 | 0 | Abstain |
| Aberdeen | 0 | 0 | 99,340 | 0 | Abstain |
| Brighthouse | 32,090 | 0 | 57,483 | 0 | Abstain |
| Lincoln Financial | 17,056 | 0 | 60,806 | 0 | Abstain |
| AIG/SunAmerica | 0 | 0 | 71,404 | 0 | Abstain |
| John Hancock | 0 | 0 | 60,983 | 0 | Abstain |
| Direxion Shares ETF Trust | 0 | 0 | 55,820 | 0 | Abstain |
| ProShares | 0 | 0 | 52,590 | 0 | Abstain |
Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.
Combines 2 wordings of this item as funds reported it.
81% Majority: yes · of votes cast
Syndax Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Keith A. Katkin”): 53,552,483 for, 12,880,619 withheld, per its Form 8-K filed 2025-05-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 86,047,032 outstanding shares: 62% for, 15% withheld (77% of the company cast a for/withheld vote).
The 55 asset managers below cast 100% of the shares they voted on this item FOR (16,995,576 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,649,438 | 0 | 0 | 0 | For |
| BlackRock | 3,921,294 | 0 | 0 | 0 | For |
| Fidelity | 1,965,078 | 0 | 0 | 0 | For |
| State Street | 1,900,031 | 0 | 1,868 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,178,062 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,165,927 | 0 | 0 | 0 | For |
| Charles Schwab | 693,127 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 305,130 | 0 | Abstain |
| Exchange Place Advisors Trust | 280,520 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 227,788 | 0 | Abstain |
| Equitable | 129,993 | 0 | 83,950 | 0 | For |
| TIAA | 200,197 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 180,000 | 0 | Abstain |
| JPMorgan | 150,989 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 141,074 | 0 | 0 | 0 | For |
| Thornburg | 133,548 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 105,104 | 0 | Abstain |
| Victory Capital | 0 | 0 | 103,834 | 0 | Abstain |
| Aberdeen | 0 | 0 | 99,340 | 0 | Abstain |
| Brighthouse | 32,090 | 0 | 57,483 | 0 | Abstain |
| Lincoln Financial | 77,862 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 71,404 | 0 | Abstain |
| John Hancock | 0 | 0 | 60,983 | 0 | Abstain |
| Direxion Shares ETF Trust | 0 | 0 | 55,820 | 0 | Abstain |
| ProShares | 0 | 0 | 52,590 | 0 | Abstain |
Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.
99.8% Majority: yes · of votes cast
Syndax Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Ratification of selection of independent registered public accounting firm:”): 71,183,107 for, 71,909 against, per its Form 8-K filed 2025-05-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 86,047,032 outstanding shares: 83% for, 0.1% against (83% of the company cast a for/against vote).
The 53 asset managers below cast 99.9% of the shares they voted on this item FOR (18,445,712 for, 1,461 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,649,438 | 0 | 0 | 0 | For |
| BlackRock | 3,921,294 | 0 | 0 | 0 | For |
| Fidelity | 1,965,078 | 0 | 0 | 0 | For |
| State Street | 1,901,787 | 112 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,178,062 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,165,927 | 0 | 0 | 0 | For |
| Charles Schwab | 693,127 | 0 | 0 | 0 | For |
| Dimensional | 305,130 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 280,520 | 0 | 0 | 0 | For |
| Goldman Sachs | 227,788 | 0 | 0 | 0 | For |
| Equitable | 213,943 | 0 | 0 | 0 | For |
| TIAA | 200,197 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 180,000 | 0 | 0 | 0 | For |
| JPMorgan | 150,989 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 141,074 | 0 | 0 | 0 | For |
| Thornburg | 133,548 | 0 | 0 | 0 | For |
| Jackson National | 105,104 | 0 | 0 | 0 | For |
| Victory Capital | 103,834 | 0 | 0 | 0 | For |
| Aberdeen | 99,340 | 0 | 0 | 0 | For |
| Brighthouse | 67,260 | 0 | 22,313 | 0 | For |
| Lincoln Financial | 77,862 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 71,404 | 0 | 0 | 0 | For |
| John Hancock | 60,983 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 55,820 | 0 | 0 | 0 | For |
| ProShares | 52,590 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.
99.8% Majority: yes · of votes cast
Syndax Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Ratification of selection of independent registered public accounting firm:”): 71,183,107 for, 71,909 against, per its Form 8-K filed 2025-05-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 86,047,032 outstanding shares: 83% for, 0.1% against (83% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (148,217 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Simplify Exchange Traded Funds | 148,217 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 0 | 0 | 19,775 | 0 | Abstain |
100% fund support · no official result
The 2 asset managers below cast 100% of the shares they voted on this item FOR (7,007 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RWC Asset Management LLP | 4,870 | 0 | 0 | 0 | For |
| HC CAPITAL TRUST | 2,137 | 0 | 0 | 0 | For |
Ranked by the number of Syndax Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 86,047,032 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Kynam Capital Management, LP | 8.76% |
| 2 | BlackRock | 8.51% |
| 3 | State Street | 6.35% |
| 4 | Vanguard | 5.73% |
| 5 | Eversept Partners, LP | 4.90% |
| 6 | Fidelity | 2.46% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2.35% |
| 8 | FRANKLIN ADVISERS INC | 2.34% |
| 9 | Sofinnova Investments, Inc. | 2.32% |
| 10 | Woodline Partners LP | 2.20% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with BlackRock, Inc. | 10.21% | DEF14A |
| BlackRock | 9.93% | 13F |
| Entities affiliated with Kynam Capital Management, LP | 9.90% | DEF14A |
| Kynam Capital Management, LP | 9.90% | 13G |
| Vanguard Group | 5.66% | 13F |
| Point72 | 4.89% | 13F |
| State Street | 4.62% | 13F |
| Goldman Sachs | 4.56% | 13F |
| Citadel Advisors | 3.51% | 13F |
| Morgan Stanley | 2.65% | 13F |
Percentages above are of 86,047,032 shares outstanding, as reported by Syndax Pharmaceuticals, Inc. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Syndax Pharmaceuticals, Inc.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Syndax Pharmaceuticals, Inc.'s shareholder meeting held 2025-05-14, in the 2024-2025 proxy season, 219 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,043 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — FOR was 94% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Syndax Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-05-16.
Syndax Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.